This review aimed to answer the general question of whether autologous platelet concentrates (APCs, an autologous blood‐derivative) can improve the outcome of alveolar bone augmentation. Three clinical scenarios were assessed: horizontal/vertical bone augmentation in combination with implant placement (simultaneous approach), horizontal bone augmentation in a staged approach, and vertical bone augmentation in a staged approach. An electronic literature search strategy was conducted for each review from the outset to July 1st, 2023. The titles and abstracts (when available) of all identified studies were screened and imported into a database. If articles appeared to meet the inclusion criteria or their title and abstract had insufficient data, the full text was obtained to make the final decision. All studies that met the inclusion criteria underwent data extraction. Moreover, the references of the identified papers were screened for additional studies. After title and abstract screening and selection criteria application, 14 clinical studies were included for the qualitative analysis: seven for horizontal/vertical bone augmentation in a simultaneous approach, five for horizontal bone augmentation in a staged approach, and two for vertical bone augmentation in a staged approach. There is scarce literature regarding the added value of APCs in bone augmentation, and most studies had small sample sizes, a lack of standardized protocols, and different outcome variables, which makes comparisons between studies difficult. Out of the 14 studies, four were well‐designed randomized clinical trials, where we could find better results for the APCs groups. Most studies, particularly comparative and well‐designed studies, demonstrated beneficial and promising results of using APCs in alveolar bone augmentation. However, before high‐level evidence‐based conclusions can be drawn, more randomized clinical trials must compare the benefits of adding APCs to the gold‐standard approach.

中文翻译：

---

关于在牙槽骨增量期间使用自体血小板浓缩物的叙述性回顾：水平（同时/分期）和垂直（同时/分期）


本综述旨在回答自体血小板浓缩物（APC，一种自体血液衍生物）是否可以改善牙槽骨增强效果的一般性问题。评估了三种临床方案：水平/垂直骨增量结合种植体植入（同步方法）、分阶段方法中的水平骨增量和分阶段方法中的垂直骨增量。从一开始到 2023 年 7 月 1 日，每项综述均采用电子文献检索策略。所有已确定研究的标题和摘要（如果有）均经过筛选并导入数据库。如果文章似乎符合纳入标准或标题和摘要数据不足，则获取全文以做出最终决定。所有符合纳入标准的研究均进行了数据提取。此外，还筛选了已确定论文的参考文献以进行进一步的研究。应用标题和摘要筛选以及选择标准后，纳入了 14 项临床研究进行定性分析：其中 7 项是同步入路水平/垂直骨增量研究，5 项是分阶段水平骨增量研究，2 项是分阶段垂直骨增量研究。分阶段的方法。关于 APC 在骨增量方面的附加值的文献很少，而且大多数研究样本量小、缺乏标准化方案以及不同的结果变量，这使得研究之间的比较变得困难。在这 14 项研究中，有 4 项是精心设计的随机临床试验，我们可以在其中找到 APC 组更好的结果。 大多数研究，特别是比较研究和精心设计的研究，都证明了使用 APC 进行牙槽骨增量的有益且有前景的结果。然而，在得出高水平的基于证据的结论之前，必须进行更多随机临床试验来比较将 APC 添加到金标准方法中的益处。